Figure 4.
CCR2b enhanced anti-tumor function of Msln-CAR T cells in vivo. (A) Schematic diagram of experiments in vivo. A549-MLM cells were implanted subcutaneously into 6-week-old female NSG mice. Seven days post-tumor cell implantation, mice were infused intravenously with PBS, Msln-CAR T or Msln-CCR2b-CAR T cells (1 × 107 cells per mouse). The second injection of effector cells was performed 7 days later. Tumor growth was monitored by bioluminescence imaging every 7 days. s.c., subcutaneous; i.v., intravenous. (B) Sequential bioluminescence imaging of mice injected with PBS, Msln-CAR T, or Msln-CCR2b-CAR T cells were shown (n = 5 mice per group in three independent experiments). (C) Bioluminescence intensity of tumor cells at different time points was captured. Data represented the means ± SEM for 5 mice per group. P-values were calculated by two-way ANOVA. ***P < 0.001. (D,E) Tumor size and weight of different groups. un, undetectable. Tumor weights were analyzed by one-way ANOVA, and data represented the means ± SEM. ***P < 0.001.